Dual-pathway Inhibition with Low-dose Aspirin and Rivaroxaban versus Aspirin Monotherapy in Patients with Coronary Artery Disease and Peripheral Artery Disease: Systematic Literature Review and Meta-analysis

Dual-pathway Inhibition with Low-dose Aspirin and Rivaroxaban versus Aspirin Monotherapy in Patients with Coronary Artery Disease and Peripheral Artery Disease: Systematic Literature Review and Meta-analysis

Background: Low-dose aspirin lowers cardiovascular event risk; dual-pathway inhibition (DPI) using low-dose aspirin with low-dose rivaroxaban may reduce this risk further. A systematic literature review and meta-analysis compared the efficacy, safety and net clinical benefit (NCB) of DPI with aspiri...

Full description

Bibliographic Details
Main Authors:	Dirk Sibbing, Michael J Blaha, Rajinder Chawla, Augusto Lavalle-Cobo, Amit Kishore, Angel Lanas, Li Li, Francesca Santilli, Oliver Schnell, Zhongwei Shi
Format:	Article
Language:	English
Published:	Radcliffe Medical Media 2024-04-01
Series:	European Cardiology Review
Online Access:	https://www.ecrjournal.com/articleindex/ecr.2023.40

Similar Items

Needs-based considerations for the role of low-dose aspirin along the CV risk continuum
by: Francesca Santilli, et al.
Published: (2024-06-01)

Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
by: Eduardo Ramacciotti MD, PhD, et al.
Published: (2022-01-01)

Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials
by: Debasu Z, et al.
Published: (2022-09-01)

Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
by: Shalin Rawal, et al.
Published: (2022-06-01)

Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran
by: Zahra Goudarzi, et al.
Published: (2025-03-01)

Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease
by: Hamzah Khan, et al.
Published: (2022-08-01)

Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery
by: Jianyu Qu, et al.
Published: (2021-06-01)

Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study
by: Kerstin Jurk, et al.
Published: (2022-05-01)

Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular disease
by: Xiao-Ying Li, et al.
Published: (2022-09-01)

Description of 3 Cases in Vietnam of Aspirin Desensitization in Patients With Coronary Artery Disease and Coexisting Aspirin Hypersensitivity
by: Dinh Van Nguyen, MD, et al.
Published: (2012-01-01)

Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention in patients with coronary artery disease: a meta-analysis
by: Di Liu, et al.
Published: (2023-10-01)

Dual-Pathway Inhibition with Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients with Coronary Artery Disease
by: Laszlo A. Groh, et al.
Published: (2023-12-01)

Safety Comparison of Monotherapy Aspirin to Dual Antiplatelet Therapy Following Coronary Artery Bypass Surgery
by: Scott D. Nei PharmD, et al.
Published: (2022-09-01)

Rivaroxaban plus aspirin vs. dual antiplatelet therapy in endovascular treatment in peripheral artery disease and analysis of medication utilization of different lesioned vascular regions
by: SiYan Huo, et al.
Published: (2023-11-01)

Fixed combination of rivaroxaban and Aspirin: Tablet formulation and analytical method validation
by: Hani Naseef, et al.
Published: (2024-08-01)

Patients with Atrial Fibrillation are Unlikely to Benefit from Aspirin Monotherapy
by: Wang N, et al.
Published: (2024-05-01)

To be or not to be on: aspirin and coronary artery bypass graft surgery
by: Aashray K. Gupta, et al.
Published: (2024-08-01)

Aspirin Hypersensitivity in Patients with Coronary Artery Disease: An Updated Review and Practical Recommendations
by: Luigi Cappannoli, et al.
Published: (2024-10-01)

Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease.
by: Sanne Bøjet Larsen, et al.
Published: (2015-01-01)

Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease
by: Zhang JW, et al.
Published: (2017-08-01)

Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease
by: Oliver Buchhave Pedersen, et al.
Published: (2021-07-01)

Impact of aspirin dosage on prognosis and coronary artery complications in pediatric Kawasaki disease patients
by: Liuyan Pan, et al.
Published: (2024-11-01)

Blood loss after coronary artery bypass by aspirin responsiveness assessed with preoperative VerifyNow aspirin testing
by: Laura M. Willemsen, et al.
Published: (2021-12-01)

ASPIRIN USE AND CHRONIC DISEASES
by: Hennekens, C, et al.
Published: (1990)

Aspirin in ischemic heart disease.
by: Hennekens, C, et al.
Published: (1992)

A Review of Aspirin-exacerbated Respiratory Diseases and Immunological Efficacy of Aspirin Desensitization
by: Hossein Esmaeilzadeh, et al.
Published: (2022-10-01)

Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease
by: Rachel Howe, et al.
Published: (2014-01-01)

Clopidogrel combined with rivaroxaban in peripheral artery disease after revascularization
by: Min Lu, et al.
Published: (2025-01-01)

Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban
by: Jose Luiz Colleoni, et al.

Effects of cigarette smoking on older chinese men treated with clopidogrel monotherapy or aspirin monotherapy: a prospective study
by: Yulun Cai, et al.
Published: (2020-07-01)

Comparison of effectiveness of aspirin, clopidogrel and cilostazol monotherapy treatment in ischaemic stroke
by: Endarwati Tuti, et al.
Published: (2025-01-01)

Carotid Ultrasound‐Based Plaque Score for the Allocation of Aspirin for the Primary Prevention of Cardiovascular Disease Events: The Multi‐Ethnic Study of Atherosclerosis and the Atherosclerosis Risk in Communities Study
by: Omar Dzaye, et al.
Published: (2024-06-01)

Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting
by: Rakesh K Sharma, et al.
Published: (2009-11-01)

Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial.
by: Catalano, M, et al.
Published: (2007)

Continuous aspirin treatment improves cardiovascular events and all-cause mortality in hemodialysis patients with peripheral artery disease
by: Chung-Kuan Wu, et al.
Published: (2024-12-01)

Effect of Low-dose, Enteric Coated Aspirin on Gastrointestinal Bleeding in Patients with Coronary Artery Disease
Published: (2008-09-01)

Evaluation of high-dose aspirin elimination in the treatment of Kawasaki disease in the incidence of coronary artery aneurysm
by: Farima Sanati, et al.
Published: (2021-01-01)

Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion
by: Dane D. Gruenebaum, et al.
Published: (2014-01-01)

Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis
by: Xiehui Chen, et al.
Published: (2021-10-01)

The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]
by: Mesana Thierry G, et al.
Published: (2005-10-01)